このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

血管新生型加齢黄斑変性症で Beovu を投与された患者の体液の解像度と有効性を評価するための観察研究 (BLUE SKY)

2026年11月17日 更新者:Novartis Pharmaceuticals

血管新生加齢黄斑変性症の主要な治療計画の下で Beovu (Brolucizumab) を投与されている患者の体液分解能と有効性を評価するための観察研究

This study was a prospective, non-interventional, multicenter, open-label study in nAMD and DME patients being treated with brolucizumab according to the EU SmPC.

An observational study design, without a strict, mandated visit schedule or mandated treatment regimen was chosen as the most appropriate to collect available data in a real life setting. For that reason, this NIS did not impose a therapy protocol, diagnostic/therapeutic procedure or a visit schedule. The diagnostic or monitoring procedures were only those ordinarily applied to the therapeutic strategy and to routine clinical care and took place as per investigator's discretion. This included e.g. visit frequency, injection frequency and types of assessments performed - only data from routine medical practice was collected as part of the study.

調査の概要

詳細な説明

BLUE SKY consisted of the nAMD-related module BIRL (Brolucizumab In Real Life) and two general, indication-related study modules "BLUE SKY AMD" and "BLUE SKY DME".

Patients were enrolled at 40 centers, which were representatively distributed amongst the 16 German federal states. This should reflect all state-specific health insurance laws and guidelines. Naïve and pre-treated patients were included after decision to start treatment with brolucizumab and consent was given.

All patients were documented either in the AMD or DME-module (Full Analysis Set).

For the BIRL module, only naïve nAMD patients enrolled in 7 selected centers were planned to be documented. All these centers were equipped with the Zeiss PlexElite OCT-A, needed to assess and analyze BIRL specific objectives in a comparable setting. Only images from routine medical practice were collected as part of the study. The study eye was defined as the first eye treated during the study, the other eye was considered as fellow eye. If both eyes were treated at baseline, the eye with the worse VA was chosen as the study eye (if VA was measured equal, the treating ophthalmologist defines the study eye upon his discretion). The prospective observation period per patient was up to 24 months.

研究の種類

観察的

入学 (実際)

572

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Aschersleben、ドイツ、06449
        • Novartis Investigative Site
      • Bayreuth、ドイツ、95445
        • Novartis Investigative Site
      • Berlin、ドイツ、10713
        • Novartis Investigative Site
      • Berlin、ドイツ、14163
        • Novartis Investigative Site
      • Bonn、ドイツ、53105
        • Novartis Investigative Site
      • Breisach、ドイツ、79206
        • Novartis Investigative Site
      • Chemnitz、ドイツ、09113
        • Novartis Investigative Site
      • Cologne、ドイツ、50968
        • Novartis Investigative Site
      • Dresden、ドイツ、01067
        • Novartis Investigative Site
      • Dresden、ドイツ、01324
        • Novartis Investigative Site
      • Esslingen am Neckar、ドイツ、73728
        • Novartis Investigative Site
      • Glauchau、ドイツ、08371
        • Novartis Investigative Site
      • Homburg、ドイツ、66421
        • Novartis Investigative Site
      • Hösbach、ドイツ、63768
        • Novartis Investigative Site
      • Kiel、ドイツ、24103
        • Novartis Investigative Site
      • Leipzig、ドイツ、04106
        • Novartis Investigative Site
      • Magdeburg、ドイツ、39104
        • Novartis Investigative Site
      • Marienberg、ドイツ、09496
        • Novartis Investigative Site
      • Münster、ドイツ、48145
        • Novartis Investigative Site
      • Neubrandenburg、ドイツ、17036
        • Novartis Investigative Site
      • Schönebeck、ドイツ、39218
        • Novartis Investigative Site
      • Stralsund、ドイツ、18435
        • Novartis Investigative Site
      • Sulzbach、ドイツ、66280
        • Novartis Investigative Site
      • Torgau、ドイツ、04860
        • Novartis Investigative Site
      • Waren、ドイツ、17192
        • Novartis Investigative Site
      • Würzburg、ドイツ、97080
        • Novartis Investigative Site
    • Bavaria
      • Munich、Bavaria、ドイツ、81377
        • Novartis Investigative Site
      • Neuburg A.d. Donau、Bavaria、ドイツ、86633
        • Novartis Investigative Site
      • Würzburg、Bavaria、ドイツ、97080
        • Novartis Investigative Site
      • Würzburg、Bavaria、ドイツ、97070
        • Novartis Investigative Site
    • Hesse
      • Frankfurt am Main、Hesse、ドイツ、60590
        • Novartis Investigative Site
    • Lower Saxony
      • Göttingen、Lower Saxony、ドイツ、37075
        • Novartis Investigative Site
      • Osnabrück、Lower Saxony、ドイツ、49076
        • Novartis Investigative Site
    • Mecklenburg-Vorpommern
      • Rostock、Mecklenburg-Vorpommern、ドイツ、18057
        • Novartis Investigative Site
    • Rhineland-Palatinate
      • Trier、Rhineland-Palatinate、ドイツ、54296
        • Novartis Investigative Site
    • Saarland
      • Saarbrücken、Saarland、ドイツ、66111
        • Novartis Investigative Site
    • Saxony
      • Dresden、Saxony、ドイツ、01307
        • Novartis Investigative Site
      • Leipzig、Saxony、ドイツ、04103
        • Novartis Investigative Site
      • Schneeberg、Saxony、ドイツ、08289
        • Novartis Investigative Site
    • Saxony-Anhalt
      • Halle、Saxony-Anhalt、ドイツ、06118
        • Novartis Investigative Site
    • Thuringia
      • Jena、Thuringia、ドイツ、07740
        • Novartis Investigative Site

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~99年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

Patients being treated for nAMD or DME with brolucizumab were enrolled in the study upon signing an informed consent.

説明

Inclusion Criteria:

The unit of analysis was patient-eye, i.e. all criteria were applied to the study eye, unless otherwise specified. Patients were included in the study if they fulfilled the following requisites:

  1. Diagnosis of nAMD or visual impairment due to DME
  2. Male and Female nAMD and DME patients with ≥18 years of age at index
  3. Decision to treat with brolucizumab at baseline visit
  4. Signed written informed consent
  5. Patients for whom a therapy with brolucizumab was medically indicated
  6. Intraretinal and/or subretinal fluid affecting the central subfield of the study eye at Screening

Exclusion Criteria:

  1. Patients with any contraindication or who were not eligible for treatment with brolucizumab as according to the SmPC
  2. Patients treated for RVO or CNV other than nAMD
  3. Receipt of any anti-VEGF treatment other than brolucizumab in the study eye at index date
  4. Central subfield of the study eye affected by fibrosis or geographic atrophy or total area of fibrosis >50% of the total lesion (nAMD)
  5. Any active intraocular or periocular infection or active intraocular inflammation in either eye at index date
  6. Patients who have been on anti-VEGF treatment for longer than 3 years (before index date)
  7. Any medical or psychological condition in the treating physician's opinion which may have prevented the patient from the 24 months study participation
  8. Patients participating in parallel in an interventional clinical trial
  9. Patients participating in parallel in any other NIS generating primary data for an anti-VEGF drug
  10. Laser photocoagulation (focal/grid or panretinal) in the study eye during the 3-month period prior to baseline
  11. Prior use of intraocular or periocular corticosteroids in the study eye provided at least 4 months prior to baseline
  12. Pregnancy and breast-feeding

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:PROSPECTIVE

コホートと介入

グループ/コホート
介入・治療
treatment naïve patients

Patients being the first time treated for nAMD or DME

There was no treatment allocation. Patients administered Brolucizumab by prescription that had started before inclusion of the patient into the study were enrolled.

pre-treated patients

Patients already being treated for nAMD or DME

There was no treatment allocation. Patients administered Brolucizumab by prescription that had started before inclusion of the patient into the study were enrolled.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Percentage of patients' eyes that are absent of subretinal fluid (SRF) and intra-retinal fluid (IRF)
時間枠:Month 12

This outcome measure is part of the BLUE SKY AMD module. This primary study objective was addressed considering treatment naïve and pre-treated patient eyes, analyzed as two independent groups (naïve and switch).

Month 12
Mean change in visual acuity (VA) under clinic specific routine treatment schemes
時間枠:Baseline, month 12

This outcome measure is part of the BIRL module. This primary study objective was addressed considering treatment naïve patient eyes.

Index date (Baseline): defined as the date of the first anti-VEGF injection (brolucizumab) in patient eye.

Baseline, month 12
Morphological CNV-Changes under clinic specific routine treatment schemes
時間枠:Baseline, month 12

This outcome measure is part of the BIRL module. This primary study objective was addressed considering treatment naïve patient eyes.

Index date (Baseline): defined as the date of the first anti-VEGF injection (brolucizumab) in patient eye.

Baseline, month 12
Percent of patients maintained on q12w dosing after loading through Week 52
時間枠:After loading, month 12

This outcome measure is part of the BLUE SKY DME module. This primary study objective was addressed considering treatment naïve patient eyes included in the study.

After loading, month 12
Change in interval length from last interval before switch (baseline) to last interval at end of follow-up (12 months)
時間枠:Baseline, month 12

This outcome measure is part of the BLUE SKY DME module. This primary study objective was addressed considering pre-treated patient eyes. Index date (Baseline): defined as the date of the first anti-VEGF injection (brolucizumab) in patient eyes.

Baseline, month 12

二次結果の測定

結果測定
メジャーの説明
時間枠
Characterize nAMD patients who initiated treatment with brolucizumab with the respect to baseline characteristics
時間枠:Baseline

nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Baseline
Evaluate anatomical parameters during treatment with brolucizumab
時間枠:Up to month 24

nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan.

Up to month 24
Evaluate VA change from baseline during treatment with brolucizumab
時間枠:Baseline, month 24

nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan.

Baseline, month 24
Estimate number of anti-VEGF injections, visits and injection intervals
時間枠:Up to month 24

nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Up to month 24
Estimate percentage of switchers during first 6 months and characterize switchers
時間枠:Baseline, month 6

nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Baseline, month 6
Estimate discontinuation rate and time to discontinuation
時間枠:Month 1-12 and 13-24

nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Month 1-12 and 13-24
Assess retreatment criteria
時間枠:Up to month 24

nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Up to month 24
Estimate the number of OCT
時間枠:Month 1-12 and 13-24

nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Month 1-12 and 13-24
Assess the safety of brolucizumab
時間枠:Up to month 24

nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Up to month 24
Evaluate anatomical effectiveness
時間枠:Up to month 24

naive nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Up to month 24
Evaluate treatment intervals
時間枠:Up to month 24

naive nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Up to month 24
Describe implementation of treatment schemes into clinical practice
時間枠:Up to month 24

naive nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Up to month 24
Evaluate morphological changes under brolucizumab treatment using multimodal imaging
時間枠:Up to month 24

naive nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Up to month 24
Percentage of patient's eyes with absence of IRF and/or SRF at month 12 (naive and switch)
時間枠:Month 12

DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Month 12
Evaluate anatomical parameters during treatment with brolucizumab
時間枠:Month 1-12 and 13-24

DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Month 1-12 and 13-24
Characterize VA change from baseline during treatment with brolucizumab
時間枠:Month 1-12 and 13-24

DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Month 1-12 and 13-24
Estimate discontinuation rate during first year of brolucizumab treatment
時間枠:Baseline, month 12

DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Baseline, month 12
Estimate time to discontinuation (persistence)
時間枠:Up to month 24

DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Up to month 24
Estimate the treatment burden
時間枠:Month 1-12 and 13-24

DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Month 1-12 and 13-24
Estimate the number of OCT and the number of visits with/without OCT
時間枠:Month 1-12 and 13-24

DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan.

Month 1-12 and 13-24
Assess safety of brolucizumab
時間枠:Up to month 24

DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan.

Up to month 24

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Novartis Pharmaceuticals、Novartis Pharmaceuticals

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2020年3月18日

一次修了 (実際)

2025年11月17日

研究の完了 (実際)

2025年11月17日

試験登録日

最初に提出

2020年9月4日

QC基準を満たした最初の提出物

2020年9月4日

最初の投稿 (実際)

2020年9月10日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月20日

QC基準を満たした最後の更新が送信されました

2026年11月17日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

追加の関連 MeSH 用語

その他の研究ID番号

  • CRTH258ADE02

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する